Lecanemab Fails to Get EU Marketing Approval; Eisai to Seek Reexamination
By Denny Jacob
Biogen and Eisai disclosed that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion on marketing authorization approval for early Alzheimer's disease treatment Lecanemab.
Eisai said it will seek reexamination of the opinion and its Chief Clinical Officer, Lynn Kramer, stated that the company was extremely disappointed by the Committee for Medicinal Products for Human Use's negative opinion.
The biopharmaceutical company's Lecanemab is already approved in the U.S., Japan, China and other countries. It's being marketed in the U.S., Japan and China.
Eisai serves as the lead for Lecanemab's development and regulatory submissions globally. Both Eisai and Biogen co-commercialize and co-promote the product, while Eisai has final decision making authority.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
July 26, 2024 08:15 ET (12:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Is 16% a Good Return?
-
Should Emerging-Markets Stocks Stand Alone in Your Portfolio?
-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued